Management of Uncontrolled Hyperglycemia on Empagliflozin-Metformin Without Insulin

Introduction to Management Strategies

The American Diabetes Association guidelines state that when blood glucose levels reach 300-350 mg/dL or greater, insulin therapy should be strongly considered from the outset, though at 270 mg/dL, patients are approaching this threshold 1, 2
Prolonged hyperglycemia at this level increases the risk of complications and should not be allowed to persist for many months 3

GLP-1 receptor agonists provide robust glucose lowering when added to metformin and SGLT2 inhibitors, with the added benefits of weight loss and low hypoglycemia risk 4, 5
These agents work through complementary mechanisms: enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety 6
They can be combined with both metformin and empagliflozin (SGLT2 inhibitor) since all three have different mechanisms of action 5, 3

The American Diabetes Association explicitly states that insulin therapy should not be delayed in patients not achieving glycemic goals 4
At blood glucose levels approaching 300 mg/dL, insulin becomes increasingly necessary to prevent complications 1, 2
Basal insulin can be started at low doses (10 units or 0.1-0.2 units/kg) and titrated gradually, often remaining as a single daily injection 4, 3
Modern basal insulin analogs (glargine, detemir, degludec) have a lower hypoglycemia risk than older formulations 1, 2

Check HbA1c if not recently done to assess chronic control 6
Assess for symptoms of hyperglycemia (polyuria, polydipsia, weight loss) or catabolic features that would mandate insulin 1, 2
Rule out acute illness, medication non-adherence, or dietary indiscretion as reversible causes 3

Explain that diabetes is a progressive disease requiring escalating therapy over time 3
Address insulin fears directly: modern insulins are safer, easier to use, and may be temporary 1, 2
Emphasize that delaying appropriate therapy increases the risk of blindness, kidney failure, amputations, and cardiovascular events 1

Do not continue ineffective therapy for months hoping for improvement - this leads to irreversible complications 3
Do not add a third oral agent if the patient is likely to need insulin anyway (HbA1c >8.5%) 3
Avoid triple oral therapy without close monitoring and prompt reassessment if unsuccessful 3
Do not use SGLT2 inhibitors in patients with recurrent genitourinary infections or at risk for ketoacidosis 5

For patients with severe hyperglycemia who refuse insulin therapy, the American Diabetes Association recommends initiating a GLP-1 receptor agonist (such as liraglutide or dulaglutide) combined with metformin as the most effective non-insulin alternative, while simultaneously engaging in intensive patient education about the temporary nature and safety of modern insulin therapy 7

The American Diabetes Association advises against using SGLT2 inhibitors in patients with recurrent genitourinary infections or at risk for ketoacidosis, and against using sulfonylureas in elderly patients or those with hypoglycemia risk factors, including end-stage liver or kidney disease 7

The American Diabetes Association recommends against using sliding scale insulin alone, and instead suggests scheduled basal-bolus regimens, with basal insulin started at 10-20 units daily (0.2-0.3 units/kg) using glargine, detemir, or degludec, and increased by 2 units every 3 days if fasting glucose remains >150 mg/dL without hypoglycemia 7